BioCryst Pharmaceuticals, Inc.
NASDAQBCRX downgraded to Sector Perform from Outperform by RBC Capital; target cut to $11 from $13, implying 25% downside from $8.81 close.
BioCryst Pharmaceuticals is trading with a striking divergence this week: short interest remains historically elevated at 15.3% of the float, yet options traders are the most bullish they have been all year. The…
BioCryst Pharmaceuticals is sending conflicting signals. Short sellers are rebuilding aggressively. Options traders are betting the other way at a year-low intensity. The gap between those two camps has widened sharply…
Snapshot as of 20 Sept 2026
BioCryst Pharmaceuticals heads into the final week of June with a striking divergence: short interest is climbing to a one-month high while options traders have swung to their most bullish posture in at least a…
BioCryst Pharmaceuticals enters late May with short sellers holding a firm grip — and the cost to maintain that position just jumped sharply. Short interest is running near 18% of the free float, a level that has…
BioCryst Pharmaceuticals heads into the post-earnings period with a striking bifurcation: short interest has jumped back toward cycle highs while borrowing costs have crashed to their lowest levels of the year — a…
BioCryst Pharmaceuticals heads into its May 4 Q1 earnings call with short sellers rebuilding positions at pace — and options traders turning more defensive than at any point in recent memory. The week's most striking…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BCRX — free to start on ORTEX.
Sign up for free →Open BCRX on ORTEX